Rina-S用于非小细胞肺癌的II 期研究｜NCT07288177

一分钟看懂

这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Rina-S，当前状态为招募中。登记地点显示中国上海、北京、长春、南京等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。

Rina-S · II 期

年龄范围：18岁及以上

登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。

登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。

以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。

Shanghai East Hospital · 上海
Beijing Cancer Hospital · 北京
Beijing Chest Tumor Hospital · 北京
Jilin Provincial Cancer Hospital · 长春
Nanjing Medical University (NMU) - Jiangsu Province Hospital (First Affiliated Hospital) · 南京
Tianjin Medical University Cancer Institute and Hospital · 天津
The First Affiliated Hospital of Hebei North University · Zhangjiakou
Henan Cancer Hospital · 郑州

以下为摘录，请打开原始登记查看完整入排标准。

* Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative surgery or radiotherapy.
* Participant must have radiological disease progression while on or after receiving the most recent regimen.
* Participants either may have actionable genetic alterations (AGAs) or no AGAs.
* Participant has measurable disease according to RECIST v1.1.
* Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1.
Key Exclusion Criteria (all study cohorts):
* Participant has NSCLC with histology other than adenocarcinoma
* Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS ≥ 90%), including, but not limited to, adequately treated cervical carcinoma of stage 1B or less, in situ basal cell or squamous cell skin carcinoma, in situ bladder cancer, ductal carcinoma in situ, or any past malignancy considered cured for ≥ 3 years.

请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。

登记号：NCT07288177；登记信息更新于 2026-10-06；本站同步于 2026-10-07，中国中心当前名额未经人工确认。